期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

恶性黑色素瘤的药物治疗现状 被引量：1

Malignant melanoma treatment of status quo
原文传递
导出
摘要 恶性黑色素瘤是恶性程度高的肿瘤，其预后差，尤其是转移性的恶性黑色素瘤仍较难治疗。达卡巴嗪已不再显示其优越性。随着近年来对恶性黑色素瘤的深入研究，新的化疗药物、免疫、靶向药物治疗显示出了好的应用前景。 Melanoma melanoma is a kind of high degree of malignancy tumor,and has poor prognosis. Specifically metastatic melanoma remains a difficult disease to treat. Dacarbazine no longer shows its superiority. In recent years,with the further study of malignant melanoma,new chemotherapy drugs,targeted therapy and immune therapy show good prospect.
作者 张铁寒 高全立
机构地区 郑州大学附属肿瘤医院生物治疗科
出处 《中国实用医刊》 2014年第11期82-84,共3页 Chinese Journal of Practical Medicine
关键词 恶性黑色素瘤 化疗 治疗现状 Malignant melanoma Chemotherapy Treatment status quo
分类号 R739.5 [医药卫生—肿瘤]
  • 相关文献

参考文献16

  • 1Eggermont AM, Schadendorf D. Melanoma and immunotherapy [ J ]. Hematol Oncol Clin North Am,2009,23 (.3) :547-64.
  • 2Baleh CM, Buzaid AC, Seong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma[ J]. J Clin Oneol, 2001,19 (16) : 3635-3648.
  • 3郭军.恶性黑色素瘤治疗的新进展[J].临床肿瘤学杂志,2007,12(12):881-884. 被引量：25
  • 4Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma [ J ]. J Chn Oneol, 2000,18 ( 1 ) : 158-166.
  • 5Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma:a phase III study [ J ]. J Clin Onco1,2004,22 (6) : 1118-1125.
  • 6Spitler LE ,Groddbard ML,Ernstoff MS ,et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colonystimulating factor[J]. J Clin Oncol,2008,18 (8) :1614-1621.
  • 7Lawson DH, Lee SJ, Tarhini AA, et al. FA697: Phase III coopera- tive group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of pa- tients with completely reseeted stage III - IV melanoma [ J ]. J Clin Oncol,2010,28 : 15s.
  • 8Petrella TM ,Tozer R, Belanger K, et al. Interleukin-21 has activity in patients with metastatic melanoma: a phase H study[ J]. J Clin Oncol,2012, 30(27) :3396-3401.
  • 9Agop Y. Bcl-2 antisense(obtimersen sodium)plus dacarbazine in patients with advanced melanoma:the oblimersen melanoma study group [ J ]. JCO, 2006,24(29) :4738-4745.
  • 10Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation[J]. N Engl J Med Jun, 2011,364 ( 26 ) :2507-2516.

二级参考文献27

  • 1Agop Y. Bcl-2 antisense ( oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the oblimersen melanoma study group[ J ]. JCO, 2006, 24 (29) :4738 - 4745.
  • 2Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma [ J ]. Proc Natl Acad Sci U S A, 2003, 100:8372- 8377.
  • 3Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients[J]. Proc Natl Acad Sci U S A, 2003, 100:4712 -4717.
  • 4Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anticytotoxic T-lymphocyte antigen-4 [ J]. J Clin Oncol, 2005, 23:6043 -6053.
  • 5Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase Ⅰ trial of a fully human anticytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages Ⅲ and Ⅳ melanoma[J]. J Clin Oncol, 2005, 23:741 -750.
  • 6Ribas A, Camacho LH, I.opez-Berestein G, et al. Antitumor activity in melanoma and antiself responses in a phase Ⅰ trial with the anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206 [ J ]. J Clin Oncol, 2005, 23:8968 - 8977.
  • 7Maker AV, Phan GQ, Attia P, et al. Tumor regression and auto- immunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase Ⅰ/Ⅱ study [J]. Ann Surg Oncol, 2005, 12:1005 -1016.
  • 8Blansfield JA, Beck KE, Tran K, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer[ J ]. J Immunother, 2005, 28 : 593-598.
  • 9Moschos SJ, Edington HD, Land SR, et al. Neoadjuvant treatment of regional stage Ⅲ B melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses [ J ]. J Clin Oncol, 2006, 24:3164-3171.
  • 10Kirkwood JM, Strawderman MH, Emstoff MS. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684[ J]. J Clin Oncol, 1996, 14(1 ):7- 17.

共引文献24

引证文献1

二级引证文献4

中国实用医刊
2014年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部